

Pfizer executes commercial license agreements for novel human vaccines based on Cytos Biotechnology's Immunodrug™ technology

Cytos Biotechnology to receive payments for execution of commercial license agreements

Schlieren (Zurich), Switzerland, January 5, 2009 – Cytos Biotechnology Ltd (SIX:CYTN) announced today that Pfizer Vaccines LLC (Pfizer) has exercised its options under the exclusive global research, option and license agreement signed by the two companies in August 2008 and has taken commercial licenses for specified vaccines based on Cytos Biotechnology's Immunodrug™ technology. These vaccines incorporate specific disease targets, which are outside the scope of Cytos Biotechnology's own R&D programs, and Cytos Biotechnology retains its rights to develop, manufacture and commercialize vaccines against different disease targets in the same human diseases.

The event triggers payments to Cytos Biotechnology for the execution of the commercial license agreements and Pfizer acquires world-wide exclusive rights to develop, manufacture and commercialize the specified vaccines.

Mark Dyer, PhD, Executive Vice President Business Development of Cytos Biotechnology commented: "The decision to execute these commercial license agreements is a measure of the importance Pfizer places on Cytos Biotechnology's Immunodrugs™ as a key component of their vaccines' pipeline. These target-focused deals, outside the scope of our own R&D programs, further validate Cytos Biotechnology's strategy to leverage its technology, know-how, and intellectual property and enable top-tier pharmaceutical companies to advance their therapeutic vaccines."

For further information about the Immunodrug™ agreement between Pfizer and Cytos Biotechnology in human health, see Cytos Biotechnology Press Release dated August 15, 2008.

For further information please contact:

Claudine Blaser, PhD
Director Corporate Communications
Cytos Biotechnology Ltd
Phone: +41 44 733 47 20
Fax: +41 44 733 47 18
e-Mail: claudine.blaser@cytos.com
Website: www.cytos.com

About Cytos Biotechnology

Cytos Biotechnology Ltd is a public Swiss biotechnology company that specializes in the discovery, development and commercialization of a new class of biopharmaceutical products – the Immunodrugs™. Immunodrugs™ are intended for use in the treatment and prevention of common chronic diseases, which afflict millions of people worldwide. Immunodrugs™ are designed to instruct the patient's immune system to produce desired therapeutic antibody or T cell responses that modulate chronic disease processes. Taking advantage of the high flexibility of its Immunodrug™ platform, Cytos Biotechnology has built a diversified pipeline of different Immunodrug™ candidates in various disease areas, of which five are currently in clinical development. The Immunodrug™ candidates are developed both in-house and together with Novartis, Pfizer and Pfizer Animal Health. Founded in 1995 as a spin-off from the Swiss Federal Institute of Technology (ETH) in Zurich, the company is located in Schlieren (Zurich). Currently, the company has 133 employees. Cytos Biotechnology Ltd is listed on the SIX Swiss Exchange (SIX:CYTN).

This foregoing press release may contain forward-looking statements that include words or phrases such as “intend”, “designed” or other similar expressions. These forward-looking statements are subject to a variety of significant uncertainties, including scientific, business, economic and financial factors, and therefore actual results may differ significantly from those presented. There can be no assurance that any therapeutic entities will enter clinical trials, that clinical trial results will be predictive for future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forward-looking statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or purchase any securities of Cytos Biotechnology Ltd.